Allergan gets clearance to buy Inamed

Allergan has received approval from antitrust authorities in Germany and Spain for its acquisition of Inamed.

Germany and Spain were the only approvals needed outside the US for the deal to go through and Allergen is now waiting on the US Federal Trade Commission to give its clearance.

For US clearance to occur the firm needs to wait for Inamed to sell off or return its licence for Reloxin, a rival to Botox.

David Pyott, Allergan chairman, president, and chief executive, said: “We are pleased to have cleared all antitrust hurdles outside of the United States.

“We continue to make good progress in our liaison with the US regulatory authorities and anticipate receiving clearance from the Federal Trade Commission in the near future so that we may consummate the acquisition.”

The deal to buy Innamed, which produces breast implants, skin treatments and treatments for obesity, was first announced in December and is thought to worth around $3 billion.

© Adfero Ltd